Get the Stockscreener App
113.12
21.96%
20.37
After Hours:
112.50
-0.62
-0.55%
Biontech Se Adr stock is traded at $113.12, with a volume of 8.71M.
It is up +21.96% in the last 24 hours and up +23.66% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$92.75
Open:
$109.29
24h Volume:
8.71M
Relative Volume:
8.19
Market Cap:
$28.42B
Revenue:
$3.26B
Net Income/Loss:
$-1.45B
P/E Ratio:
-19.27
EPS:
-5.871
Net Cash Flow:
$1.18B
1W Performance:
+21.98%
1M Performance:
+23.66%
6M Performance:
+2.45%
1Y Performance:
+1.54%
1-Day Range:
$107.18
$116.00
1-Week Range:
$90.52
$116.00
52-Week Range:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
113.12 | 23.30B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-16-26 | Upgrade | Goldman | Neutral → Buy |
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BioNTech SE Stock Jumps As Traders Bet On Post-COVID Pivot - StocksToTrade
European ADRs Rose In US Trading, Led By BioNTech - Finimize
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - Benzinga
BNTX Stock Quote Price and Forecast - CNN
U.S. Listings For German Scale-ups | Part 2 - orrick.com
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BIONTECH SE BIONTECH SE ADR (0A3M.L) Q1 FY2026 earnings call transcript - Yahoo Finance
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. - The Motley Fool
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia
BioNTech (BNTX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock - TradingView
Bank of America Corp DE Raises Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Double Whammy: A CEO Transition Lands in the Middle of a Guidance Cut () - aktiencheck.de
Assenagon Asset Management S.A. Makes New $39.38 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Second Quarter Puts a Founder's Exit and a Shrinking COVID Franchise in Sharp Relief - aktiencheck.de
Bank of New York Mellon Corp Trims Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pfizer and BioNTech Advance Next‑Season Pediatric COVID‑19 Booster Strategy With New Phase 3 Update - TipRanks
Pfizer and BioNTech Advance Variant-Adapted COVID-19 Booster in New Phase 4 Study - tipranks.com
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
Pfizer and BioNTech Lock In Next-Gen Pediatric COVID Booster Edge - TipRanks
BioNTech Earnings Call: COVID Slide, Oncology Push - tipranks.com
BioNTech SE (BNTX) Stock Forecasts - Yahoo Finance
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
Earnings call transcript: BioNTech Q2 2026 revenue falls, shares slip premarket - Investing.com
BioNTech Q2 Earnings Call Highlights - Yahoo Finance
BioNTech (BNTX) Lowers 2026 Revenue Forecast, Appoints Guido Oelkers as CEO, and Reports Q2 Net Loss of €820.8 Million - kalkinemedia.com
Weekly Recap: BioNTech CEO succession and Q2 2026 loss forecast - TradingView
BioNTech earnings on deck as losses widen amid COVID decline - Investing.com
Biontech Se Sponsored Adr (BNTXN) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BX:22UA - TradingView
Spontaneous reporting of adverse reactions... : Porto Biomedical Journal - Ovid
Weekly Recap: Q2 2026 results, investor call and Moderna IP response - TradingView
First Trust Advisors LP Acquires 451,124 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Decreases Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Biontech Se Sponsored Adr (BNTXN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (0A3M) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Earnings Dates, Call Summary & Reports - TipRanks
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029? - qz.com
BioNTech’s $1 Billion Buyback Can’t Drown Out the Noise From Patent Battles () - aktiencheck.de
Biontech Se Sponsored Adr (0A3M) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (0A3M) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
BioNTech Faces Fresh Patent Offensive as Buyback Signals Confidence, Pipeline Data Loom - aktiencheck.de
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season - TradingView
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):